SNMMI 2019: Reintroducing Therapeutics: Nuclear Medicine Physician Leading Patient Care Team

Las Vegas, Nevada (UroToday.com) Dr. Daniel Pryma gave the first presentation of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting in Las-Vegas 2019. In his talk, he gave an overview of the nuclear medicine physician leading patient care team. The field of nuclear medicine is vast and expansive, dealing with therapeutic radiopharmaceuticals which are quite […]

SNMMI 2019: Operationalizing Your Practice for 177Lu-PSMA Based Therapies

Las Vegas, Nevada (UroToday.com) Phillip Kuo, MD, PhD, gave an overview discussing important radiation safety considerations and logistical considerations for starting 177-Lutetium-PSMA targeted therapies. The physical half-life Lutetium-177 is 6.65 days. The beta-particles have an Emax of 497 keV (78.6%), 384 keV (9.1%), 176 keV (12.2%), the gamma photons with Ey of 208 kEv (11%) and […]

SNMMI 2019: Operationalizing a 177Lu-Dotatate Clinic

Las Vegas, Nevada (UroToday.com) In this presentation, Dr. Jennifer Kwak aimed to describe the factors affecting location selection for radiopharmaceutical therapy, to address regulatory and radiation safety issues in initiating a therapy program of therapeutic radiopharmaceuticals and develop a plan for patient flow management. The example she used throughout her talk was Lutetium-DOTATATE treatment. This […]

SNMMI 2019: Establishing Your Practice in Systemic Radiation Therapy in Theranostics Practice / The Role of Technologists in Theranostics Practice

Las Vegas, Nevada (UroToday.com) At the 2019 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, Dr. Sandy McEwan gave a comprehensive overview of establishing a practice in systemic radiation therapy. This important field of medicine entails the systemic administration of a targeted radionuclide utilizing short-range beta particles, alpha particles or electron emissions to […]

Structure establishment of three-dimensional (3D) cell culture printing model for bladder cancer.

Two-dimensional (2D) cell culture is a valuable method for cell-based research but can provide unpredictable, misleading data about in vivo responses. In this study, we created a three-dimensional (3D) cell culture environment to mimic tumor characteristics and cell-cell interactions to better characterize the tumor formation response to chemotherapy. We fabricated the 3D cell culture samples […]

Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer.

Mitomycin-C (MMC) and thiotepa are intravesical agents effective in reducing the recurrence of low-grade noninvasive bladder cancer when instilled perioperatively. No studies have compared these agents as a single-dose perioperative instillation. This study tests whether there is a difference in recurrence-free survival in patients with low-grade noninvasive bladder cancer who received intravesical MMC versus thiotepa. […]

Diagnostic Accuracy of Multi-Parametric Magnetic Resonance Imaging for Tumor Staging of Bladder Cancer: Meta-Analysis.

Purpose: Evaluate the diagnostic accuracy of multi-parametric magnetic resonance imaging (mp-MRI) for local staging of bladder cancer (BCa). Materials and Methods: The databases of PubMed, Web of Science, Wanfang, and CNKI were searched for related literatures about BCa diagnosed by mp-MRI from January 1, 2000 to April 12, 2019. The strict inclusion and exclusion criteria […]

Bilateral wunderlich syndrome secondary to synchronous bilateral testicular germ cell tumor. A case report.

Testicular cancer accounts for 1% of male neoplasms, the most common histology is bilateral presentation is reported in 1-2% of cases, and germ cell tumor histology represents 90-95% of cases. Especifically, choriocarcinoma as a pure component represents 0. 3-1% of these neoplasms and as a mixed component, 8%. We present a 26-year-old male patient with […]

X